Analysts Offer Predictions for Kiniksa Pharmaceuticals, Ltd.'s FY2024 Earnings (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities researchers at Wedbush cut their FY2024 EPS estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.67) per share for the year, down from their prior forecast of ($0.65). Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.05) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.65) EPS and FY2026 earnings at ($0.23) EPS.

Separately, TheStreet raised shares of Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Trading Down 0.9 %

Shares of KNSA traded down $0.16 during trading hours on Friday, reaching $17.90. The stock had a trading volume of 251,070 shares, compared to its average volume of 409,763. The firm has a 50-day simple moving average of $19.71 and a 200 day simple moving average of $17.94. Kiniksa Pharmaceuticals has a 12 month low of $10.29 and a 12 month high of $22.09. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 99.62 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. The business had revenue of $83.40 million during the quarter, compared to analyst estimates of $72.31 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%.

Insider Activity

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at approximately $383,242.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 12,742 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $21.49, for a total transaction of $273,825.58. Following the transaction, the chief executive officer now owns 70,594 shares of the company's stock, valued at approximately $1,517,065.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Michael R. Megna sold 5,126 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at $383,242.52. The disclosure for this sale can be found here. Insiders have sold 33,109 shares of company stock worth $709,929 over the last 90 days. 54.23% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank increased its position in shares of Kiniksa Pharmaceuticals by 13.8% during the 1st quarter. Swiss National Bank now owns 60,100 shares of the company's stock valued at $597,000 after purchasing an additional 7,300 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Kiniksa Pharmaceuticals by 23.8% during the first quarter. JPMorgan Chase & Co. now owns 17,825 shares of the company's stock worth $177,000 after buying an additional 3,431 shares during the last quarter. Bank of New York Mellon Corp raised its position in Kiniksa Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 137,001 shares of the company's stock worth $1,363,000 after acquiring an additional 3,095 shares during the period. BlackRock Inc. boosted its stake in Kiniksa Pharmaceuticals by 0.3% in the first quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock valued at $34,734,000 after acquiring an additional 10,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Kiniksa Pharmaceuticals by 126.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock valued at $3,588,000 after acquiring an additional 201,622 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.